US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% AMD $633.91 ▲+0.00% NVDA $233.95 ▲+0.00% JNJ $256.03 ▲+0.00% SNDK $1,719.99 ▲+0.00%
FinancialContent

Articles published by Aurinia Pharmaceuticals Inc.

< Previous 1 2 3 4 Next >
News headline image
Aurinia Settles Patent Litigation with Teva
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH KZR
News headline image
Aurinia Announces Management Transition
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Responds to Now Retracted LinkedIn Post
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia to Participate in Jefferies London Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
News headline image
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Tickers AUPH
< Previous 1 2 3 4 Next >